QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study 期刊论文 2019, 卷号: 8, 期号: 13, 页码: 5823-5830 作者:  Yang Guangjian;  Ma Di;  Xu Haiyan;  Yang Lu;  Li Junling 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 anaplastic lymphoma kinase inhibitor  crizotinib  crizotinib continuation beyond progressive disease  non-small cell lung cancer  treatment duration   QUALITATIVE EVALUATION OF ASSOCIATIONS BY THE TRANSITIVITY OF THE ASSOCIATION SIGNS 其他 2015-01-01 Jiang, Zhichao; Ding, Peng; Geng, Zhi 收藏  |  浏览/下载：1/0  |  提交时间：2017/12/03 Association measure  causal inference  Prentice&apos  surrogate endpoint  Yule-Simpson Paradox  DIRECTED ACYCLIC GRAPHS  SURROGATE END-POINTS  CAUSAL INFERENCE  CRITERIA  s criterion   Sufficient conditions for concluding surrogacy based on observed data 其他 2011-01-01 Wu, Zhenguo; He, Ping; Geng, Zhi 收藏  |  浏览/下载：3/0  |  提交时间：2015/11/10 causal effect  Prentice&apos  surrogate endpoint  END-POINTS  CLINICAL-TRIALS  PRINCIPAL STRATIFICATION  CAUSAL INFERENCE  CRITERIA  VALIDATION  s criterion   ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL 其他 2008-01-01 Qin, Li; Gilbert, Peter B.; Follmann, Dean; Li, Dongfeng 收藏  |  浏览/下载：3/0  |  提交时间：2015/11/14 Clinical trial  discrete failure time model  missing data  potential outcomes  principal stratification  surrogate marker  FAILURE TIME REGRESSION  PROPORTIONAL HAZARDS MODEL  CAUSAL INFERENCE  CLINICAL-TRIALS  COVARIATE DATA  IMMUNOGENICITY  DESIGNS